Olema Oncology's OP-3136 Shows Early Promise in Solid Tumors — Olema Pharmaceuticals, Inc.

Event summary

Olema Oncology presented initial Phase 1 data for OP-3136 at the 2026 ASCO Annual Meeting, showing tumor shrinkage in 68% of evaluable patients.
OP-3136 demonstrated acceptable tolerability with no dose-limiting toxicities observed up to 45 mg daily.
Three patients achieved partial responses, including two confirmed and one unconfirmed.
The study enrolled 32 heavily pretreated patients across advanced breast cancer, prostate cancer, and lung cancer indications.

The big picture

Olema Oncology's OP-3136 represents a novel approach to targeting KAT6, an epigenetic regulator dysregulated in multiple cancers. The early Phase 1 data suggests potential as a differentiated therapy, particularly in endocrine-resistant breast cancer. The company's focus on combination strategies aligns with broader industry trends toward multi-targeted oncology treatments. Success will depend on demonstrating sustained efficacy and manageable safety profiles in larger, controlled studies.

What we're watching

Combination Strategy: Whether OP-3136's combination with palazestrant and fulvestrant can enhance efficacy in ER+/HER2- breast cancer.
Dose Optimization: The pace at which Olema identifies the optimal dose for OP-3136's monotherapy and combination regimens.
Regulatory Pathway: How the Phase 1 data positions OP-3136 for potential accelerated development in difficult-to-treat cancers.